Handelen The Oncology Institute, Inc. - TOI CFD
Toevoegen aan favorieten- Samenvatting
- Historische gegevens
- Evenementen
- Winst- en verliesrekening
- Balans
- Cash Flow
- Eigendom
Spread | 0.08 | ||||||||
Overnight-tarief longpositie
Long position overnight fee
Ga naar platform | -0.025457% | ||||||||
Overnight-tarief shortpositie
Short position overnight fee
Ga naar platform | 0.003235% | ||||||||
Tijd van overnight-tarief | 21:00 (UTC) | ||||||||
Min. verhandelde hoeveelheid | 1 | ||||||||
Valuta | USD | ||||||||
Marge | 20% | ||||||||
Effectenbeurs | United States of America | ||||||||
Handelscommissie | 0% |
*Information provided by Capital.com
Prev. Close* | N/A |
Open* | 0.41 |
1-Jaarlijkse Verandering* | -93.83% |
Dagelijks bereik* | 0.41 - 0.49 |
52 wekelijks bereik | 0.33-8.67 |
Weekgemiddelde volume (10 dagen) | 464.54K |
Gemiddeld volume (3 maanden) | 5.44M |
Marktkapitalisatie | 26.37M |
P/E Ratio | -100.00K |
Uitstaande Aandelen | 75.35M |
Omzet | 273.51M |
EPS | -0.55 |
Dividend (opbrengst %) | N/A |
Beta | -100.00K |
Volgende inkomsten datum | Aug 7, 2023 |
Alle gegevens zijn afkomstig van Refinitiv, behalve de gegevens gemarkeerd met een sterretje, die zijn afkomstig van Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Slotkoers | Change | Change (%) | Openingskoers | High | Low |
---|---|---|---|---|---|---|
Jun 5, 2023 | 0.49 | 0.08 | 19.51% | 0.41 | 0.49 | 0.41 |
May 29, 2023 | 0.51 | 0.00 | 0.00% | 0.51 | 0.51 | 0.51 |
May 16, 2023 | 0.51 | 0.00 | 0.00% | 0.51 | 0.51 | 0.51 |
May 5, 2023 | 0.45 | 0.00 | 0.00% | 0.45 | 0.45 | 0.45 |
May 2, 2023 | 0.51 | 0.00 | 0.00% | 0.51 | 0.51 | 0.51 |
Apr 19, 2023 | 0.51 | 0.00 | 0.00% | 0.51 | 0.51 | 0.51 |
Apr 17, 2023 | 0.57 | 0.00 | 0.00% | 0.57 | 0.57 | 0.57 |
Apr 14, 2023 | 0.59 | 0.01 | 1.72% | 0.58 | 0.60 | 0.58 |
Apr 13, 2023 | 0.56 | -0.02 | -3.45% | 0.58 | 0.58 | 0.56 |
Apr 12, 2023 | 0.59 | -0.04 | -6.35% | 0.63 | 0.64 | 0.58 |
Apr 11, 2023 | 0.62 | 0.00 | 0.00% | 0.62 | 0.62 | 0.62 |
Apr 6, 2023 | 0.60 | 0.00 | 0.00% | 0.60 | 0.60 | 0.60 |
Apr 4, 2023 | 0.66 | 0.05 | 8.20% | 0.61 | 0.66 | 0.59 |
Apr 3, 2023 | 0.64 | 0.03 | 4.92% | 0.61 | 0.64 | 0.61 |
Mar 31, 2023 | 0.61 | -0.05 | -7.58% | 0.66 | 0.66 | 0.61 |
Mar 30, 2023 | 0.64 | 0.01 | 1.59% | 0.63 | 0.64 | 0.63 |
Mar 29, 2023 | 0.62 | 0.00 | 0.00% | 0.62 | 0.62 | 0.62 |
Mar 28, 2023 | 0.60 | 0.01 | 1.69% | 0.59 | 0.60 | 0.59 |
Mar 27, 2023 | 0.68 | 0.01 | 1.49% | 0.67 | 0.68 | 0.67 |
Mar 24, 2023 | 0.67 | -0.08 | -10.67% | 0.75 | 0.75 | 0.67 |
The Oncology Institute, Inc. Events
Tijd (UTC) (UTC) | Land | Evenement |
---|---|---|
Friday, June 9, 2023 | ||
Tijd (UTC) (UTC) 15:00 | Land US
| Evenement Oncology Institute Inc at Jefferies Healthcare Conference Oncology Institute Inc at Jefferies Healthcare ConferenceForecast -Previous - |
Thursday, June 15, 2023 | ||
Tijd (UTC) (UTC) 18:00 | Land US
| Evenement Oncology Institute Inc Annual Shareholders Meeting Oncology Institute Inc Annual Shareholders MeetingForecast -Previous - |
Monday, June 26, 2023 | ||
Tijd (UTC) (UTC) 10:59 | Land US
| Evenement Oncology Institute Inc at UBS Healthcare Services Summit Oncology Institute Inc at UBS Healthcare Services SummitForecast -Previous - |
Friday, July 14, 2023 | ||
Tijd (UTC) (UTC) 18:00 | Land US
| Evenement Oncology Institute Inc Annual Shareholders Meeting Oncology Institute Inc Annual Shareholders MeetingForecast -Previous - |
Monday, August 7, 2023 | ||
Tijd (UTC) (UTC) 10:59 | Land US
| Evenement Q2 2023 Oncology Institute Inc Earnings Release Q2 2023 Oncology Institute Inc Earnings ReleaseForecast -Previous - |
Tuesday, November 7, 2023 | ||
Tijd (UTC) (UTC) 10:59 | Land US
| Evenement Q3 2023 Oncology Institute Inc Earnings Release Q3 2023 Oncology Institute Inc Earnings ReleaseForecast -Previous - |
- Jaarlijks
- Per kwartaal
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Totale inkomsten | 252.483 | 203.003 | 187.515 | 155.405 | 113.16 |
Inkomsten | 252.483 | 203.003 | 187.515 | 155.405 | 113.16 |
Kosten van opbrengsten, totaal | 200.39 | 162.155 | 150.636 | 125.465 | 86.8785 |
Brutowinst | 52.093 | 40.848 | 36.879 | 29.9406 | 26.2816 |
Totale bedrijfskosten | 334.251 | 243.904 | 195.712 | 158.05 | 108.371 |
Verkoop/Algemeen/Admin. Uitgaven, Totaal | 119.689 | 83.365 | 41.898 | 29.6435 | 20.3894 |
Depreciation / Amortization | 4.411 | 3.341 | 3.178 | 2.94186 | 1.10266 |
Bedrijfsresultaat | -81.768 | -40.901 | -8.197 | -2.64476 | 4.78954 |
Renteopbrengsten (-uitgaven), netto Niet-operationeel | -4.082 | -0.32 | -0.347 | -0.00338 | -0.00159 |
Overige, Netto | 85.759 | 29.623 | -6.271 | 0.01 | 0.07277 |
Netto inkomen voor belastingen | -0.091 | -11.598 | -14.815 | -2.63813 | 4.86072 |
Netto inkomen na belastingen | 0.152 | -10.927 | -14.322 | -4.0214 | 3.94797 |
Netto inkomen voor extra. Posten | 0.152 | -10.927 | -14.322 | -4.0214 | 3.94797 |
Netto inkomen | 0.152 | -10.927 | -14.322 | -4.0214 | 3.94797 |
Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | 0.068 | -10.927 | -14.322 | -4.0214 | 3.94797 |
Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | 0.068 | -10.927 | -14.322 | -4.0214 | 3.94797 |
Verwaterd Netto Inkomen | 0.068 | -10.927 | -14.322 | -4.0214 | 3.94797 |
Verwaterd Gewogen Gemiddelde Aandelen | 80.6056 | 73.249 | 74.5784 | 74.5784 | 74.5784 |
Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | 0.00084 | -0.14918 | -0.19204 | -0.05392 | 0.05294 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Verwaterde Genormaliseerde Winst per Aandeel | 0.16291 | -0.19316 | -0.19204 | -0.05392 | 0.05294 |
Ongebruikelijke uitgaven (inkomsten) | 9.761 | -4.957 | 0 | ||
Total Adjustments to Net Income | -0.084 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Totale inkomsten | 76.192 | 71.424 | 64.977 | 116.082 | 55.161 |
Inkomsten | 76.192 | 71.424 | 64.977 | 116.082 | 55.161 |
Kosten van opbrengsten, totaal | 62.093 | 55.795 | 51.977 | 92.618 | 42.839 |
Brutowinst | 14.099 | 15.629 | 13 | 23.464 | 12.322 |
Totale bedrijfskosten | 109.059 | 96.503 | 85.074 | 152.674 | 73.449 |
Verkoop/Algemeen/Admin. Uitgaven, Totaal | 28.83 | 29.572 | 31.963 | 58.154 | 29.806 |
Depreciation / Amortization | 1.269 | 1.192 | 1.134 | 2.085 | 0.987 |
Ongebruikelijke uitgaven (inkomsten) | 16.867 | 9.944 | 0 | -0.183 | -0.183 |
Bedrijfsresultaat | -32.867 | -25.079 | -20.097 | -36.592 | -18.288 |
Renteopbrengsten (-uitgaven), netto Niet-operationeel | -1.443 | -2.45 | -1.497 | -0.135 | -0.074 |
Overige, Netto | 4.356 | 16.155 | 18.896 | 50.708 | 37.828 |
Netto inkomen voor belastingen | -29.954 | -11.374 | -2.698 | 13.981 | 19.466 |
Netto inkomen na belastingen | -29.998 | -11.007 | -2.674 | 13.833 | 19.286 |
Netto inkomen voor extra. Posten | -29.998 | -11.007 | -2.674 | 13.833 | 19.286 |
Netto inkomen | -29.998 | -11.007 | -2.674 | 13.833 | 19.286 |
Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -24.494 | -8.737 | -2.175 | 10.98 | 15.752 |
Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -24.494 | -8.737 | -2.175 | 10.98 | 15.752 |
Verwaterd Netto Inkomen | -24.494 | -8.737 | -2.175 | 10.98 | 15.832 |
Verwaterd Gewogen Gemiddelde Aandelen | 73.4491 | 72.7522 | 72.1844 | 73.7422 | 74.5515 |
Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -0.33348 | -0.12009 | -0.03013 | 0.1489 | 0.21236 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Verwaterde Genormaliseerde Winst per Aandeel | -0.17355 | -0.01811 | 0.00818 | 0.20832 | 0.24367 |
Total Adjustments to Net Income | 5.504 | 2.27 | 0.499 | -2.853 | -3.534 |
Verwateringsaanpassing | 0.08 |
- Jaarlijks
- Per kwartaal
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Totaal vlottende activa | 130.418 | 154.056 | 29.72 | 21.7927 | |
Geldmiddelen en kortetermijnbeleggingen | 73.806 | 114.299 | 5.998 | 2.4462 | |
Cash | 14.01 | 114.299 | 5.998 | 2.4462 | |
Totale Vorderingen, Netto | 40.433 | 21.244 | 17.259 | 14.7344 | |
Accounts Receivable - Trade, Net | 39.816 | 20.007 | 17.146 | 14.6163 | |
Total Inventory | 9.261 | 6.438 | 4.354 | 3.88899 | |
Prepaid Expenses | 6.918 | 11.2 | 2.109 | 0.72306 | |
Total Assets | 261.665 | 203.439 | 65.689 | 59.5207 | |
Property/Plant/Equipment, Total - Net | 33.041 | 4.192 | 2.104 | 1.5509 | |
Property/Plant/Equipment, Total - Gross | 36.547 | 6.176 | 3.262 | 2.02587 | |
Accumulated Depreciation, Total | -3.506 | -1.984 | -1.158 | -0.47497 | |
Goodwill, Net | 21.418 | 26.626 | 14.227 | 14.0767 | |
Intangibles, Net | 17.957 | 18.245 | 19.516 | 22.0026 | |
Other Long Term Assets, Total | 0.477 | 0.32 | 0.122 | 0.09785 | |
Total Current Liabilities | 29.72 | 29.798 | 28.607 | 13.5855 | |
Accounts Payable | 9.372 | 15.559 | 12.643 | 8.88543 | |
Accrued Expenses | 16.859 | 10.693 | 4.26 | 1.4805 | |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | |
Current Port. of LT Debt/Capital Leases | 0 | 0.183 | 5.368 | 0 | |
Other Current Liabilities, Total | 3.489 | 3.363 | 6.336 | 3.21952 | |
Total Liabilities | 138.49 | 99.28 | 37.588 | 17.2984 | |
Total Long Term Debt | 80.621 | 0 | 6.561 | 0 | |
Long Term Debt | 80.621 | 0 | 6.561 | 0 | |
Deferred Income Tax | 0.108 | 0.371 | 1.613 | 2.95652 | |
Other Liabilities, Total | 28.041 | 69.111 | 0.807 | 0.75643 | |
Total Equity | 123.175 | 104.159 | 28.101 | 42.2224 | |
Preferred Stock - Non Redeemable, Net | 48.1434 | ||||
Common Stock | 0.007 | 0.007 | 0.006 | 0 | |
Additional Paid-In Capital | 186.25 | 167.386 | 80.402 | 0.09401 | |
Retained Earnings (Accumulated Deficit) | -63.082 | -63.234 | -52.307 | -6.01502 | |
Total Liabilities & Shareholders’ Equity | 261.665 | 203.439 | 65.689 | 59.5207 | |
Total Common Shares Outstanding | 73.2656 | 73.249 | 74.5784 | 74.5784 | |
Other Current Assets, Total | 0 | 0.875 | |||
Total Preferred Shares Outstanding | 0.16505 | 0.16351 | |||
Korte Termijn Investeringen | 59.796 | ||||
Long Term Investments | 58.354 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Totaal vlottende activa | 118.962 | 130.418 | 143.631 | 112.205 | 139.84 |
Geldmiddelen en kortetermijnbeleggingen | 55.382 | 73.806 | 90.579 | 64.208 | 94.659 |
Cash | 15.25 | 14.01 | 64.208 | 94.659 | |
Totale Vorderingen, Netto | 46.384 | 40.433 | 35.379 | 29.369 | 25.792 |
Accounts Receivable - Trade, Net | 45.956 | 39.816 | 34.82 | 28.947 | 24.513 |
Total Inventory | 10.254 | 9.261 | 10.018 | 8.58 | 7.77 |
Prepaid Expenses | 6.942 | 6.918 | 7.655 | 10.048 | 10.744 |
Other Current Assets, Total | 0 | 0 | 0.875 | ||
Total Assets | 234.633 | 261.665 | 283.802 | 189.74 | 206.512 |
Property/Plant/Equipment, Total - Net | 34.524 | 33.041 | 31.814 | 23.269 | 22.142 |
Property/Plant/Equipment, Total - Gross | 38.57 | 36.547 | 34.86 | 25.922 | 24.436 |
Accumulated Depreciation, Total | -4.046 | -3.506 | -3.046 | -2.653 | -2.294 |
Goodwill, Net | 4.551 | 21.418 | 31.016 | 34.476 | 26.626 |
Intangibles, Net | 17.228 | 17.957 | 18.665 | 19.383 | 17.572 |
Other Long Term Assets, Total | 0.527 | 0.477 | 0.461 | 0.407 | 0.332 |
Total Current Liabilities | 30.085 | 29.72 | 32.852 | 36.128 | 31.521 |
Accounts Payable | 11.946 | 9.372 | 11.155 | 13.9 | 12.596 |
Accrued Expenses | 14.376 | 16.859 | 17.052 | 17.328 | 15.57 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 0 | 0 | 0 | |
Other Current Liabilities, Total | 3.763 | 3.489 | 4.645 | 4.9 | 3.355 |
Total Liabilities | 136.227 | 138.49 | 155.868 | 65.757 | 74.514 |
Total Long Term Debt | 82.144 | 80.621 | 79.069 | 0 | 0 |
Long Term Debt | 82.144 | 80.621 | 79.069 | ||
Deferred Income Tax | 0.082 | 0.108 | 0.554 | 0.502 | 0.551 |
Other Liabilities, Total | 23.916 | 28.041 | 43.393 | 29.127 | 42.442 |
Total Equity | 98.406 | 123.175 | 127.934 | 123.983 | 131.998 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | ||
Common Stock | 0.007 | 0.007 | 0.007 | 0.007 | 0.007 |
Additional Paid-In Capital | 191.479 | 186.25 | 180.002 | 173.377 | 175.939 |
Retained Earnings (Accumulated Deficit) | -93.08 | -63.082 | -52.075 | -49.401 | -43.948 |
Total Liabilities & Shareholders’ Equity | 234.633 | 261.665 | 283.802 | 189.74 | 206.512 |
Total Common Shares Outstanding | 73.7546 | 73.2656 | 72.3417 | 71.9809 | 73.2762 |
Total Preferred Shares Outstanding | 0.16505 | 0.16505 | 0.16505 | 0.16664 | 0.16351 |
Geldmiddelen & Equivalenten | 61.425 | ||||
Korte Termijn Investeringen | 40.132 | 59.796 | 29.154 | ||
Long Term Investments | 58.841 | 58.354 | 58.215 |
- Jaarlijks
- Per kwartaal
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Netto-inkomen/Beginsaldo | 0.152 | -10.927 | -14.322 | -4.0214 | 3.94797 |
Geldmiddelen uit Operationele Activiteiten | -61.756 | -32.68 | 0.508 | 3.61526 | 5.64181 |
Geldmiddelen uit Operationele Activiteiten | 4.411 | 3.341 | 3.178 | 2.94186 | 1.10266 |
Deferred Taxes | -0.263 | -1.242 | -1.344 | 0.82476 | 0.68877 |
Cash Taxes Paid | 0.15 | 1.727 | 0.207 | 0.06127 | 0.17281 |
Contant Betaalde Rente | 0.224 | 0.275 | 0.227 | 0.00338 | 0.00159 |
Veranderingen in het Operationeel Kapitaal | -20.163 | -14.489 | 0.992 | 3.4491 | -0.09758 |
Geldmiddelen uit Investeringsactiviteiten | -131.614 | -12.154 | -8.844 | -1.20456 | 2.4887 |
Kapitaaluitgaven | -5.529 | -3.047 | -1.194 | -1.20456 | -0.69596 |
Overige Cash Flow investeringsposten, Totaal | -126.085 | -9.107 | -7.65 | 0 | 3.18466 |
Geldmiddelen uit Financieringsactiviteiten | 92.206 | 154.01 | 11.888 | -0.00181 | -8.20041 |
Financiering van Cash Flow Posten | -5.931 | 141.261 | -0.343 | -8.20041 | |
Uitgifte (Aflossing) van Schulden, Netto | 106.279 | -7.251 | 12.181 | -0.00181 | 0 |
Nettowijziging in Geldmiddelen | -101.164 | 109.176 | 3.552 | 2.40888 | -0.0699 |
Niet-Geldelijke Posten | -45.893 | -9.363 | 12.004 | 0.42093 | |
Uitgifte (Aflossing) van aandelen, netto | -8.142 | 20 | 0.05 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -29.998 | 0.152 | 11.159 | 13.833 | 19.286 |
Cash From Operating Activities | -15.452 | -61.756 | -47.759 | -27.36 | -16.981 |
Cash From Operating Activities | 1.269 | 4.411 | 3.219 | 2.085 | 0.987 |
Deferred Taxes | -0.026 | -0.263 | 0.183 | 0.131 | 0.18 |
Non-Cash Items | 18.223 | -45.893 | -47.059 | -35.687 | -29.441 |
Cash Taxes Paid | 0.068 | 0.15 | 0.026 | 0.025 | 0 |
Cash Interest Paid | 1.128 | 0.224 | 0.184 | 0.135 | 0.074 |
Changes in Working Capital | -4.92 | -20.163 | -15.261 | -7.722 | -7.993 |
Cash From Investing Activities | 18.401 | -131.614 | -99.043 | -11.264 | -1.002 |
Capital Expenditures | -1.839 | -5.529 | -3.534 | -2.344 | -1.002 |
Other Investing Cash Flow Items, Total | 20.24 | -126.085 | -95.509 | -8.92 | 0 |
Cash From Financing Activities | -1.709 | 92.206 | 93.053 | -12.342 | -1.657 |
Financing Cash Flow Items | -1.691 | -5.931 | -4.661 | -3.653 | -1.644 |
Issuance (Retirement) of Stock, Net | -8.142 | -8.584 | -8.663 | 0 | |
Issuance (Retirement) of Debt, Net | -0.018 | 106.279 | 106.298 | -0.026 | -0.013 |
Net Change in Cash | 1.24 | -101.164 | -53.749 | -50.966 | -19.64 |
Naam investeerder | Type investeerder | Percentage uitstaand | Aandelen in bezit | Wijziging aandelen | Datum bezit | Omzetcijfer |
---|---|---|---|---|---|---|
M33 Growth LLC | Venture Capital | 20.247 | 15256383 | 0 | 2022-09-21 | |
Havencrest Capital Management LLC | Private Equity | 18.2189 | 13728194 | -452763 | 2022-11-10 | |
Fidelity Management & Research Company LLC | Investment Advisor | 15.9254 | 12000000 | -1982 | 2023-03-31 | LOW |
FOG Ventures Investments LLC | Corporation | 6.1511 | 4634908 | 0 | 2023-04-17 | LOW |
OncologyCare Partners LLC | Corporation | 5.4541 | 4109771 | 0 | 2023-04-17 | LOW |
Deerfield Management Company, L.P. | Hedge Fund | 4.4592 | 3360052 | 0 | 2023-03-31 | MED |
Jimmy Holdings, Inc | Corporation | 4.3957 | 3312216 | -554217 | 2023-03-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.5793 | 1943543 | 10937 | 2023-03-31 | LOW |
Triatomic Management LP | Investment Advisor/Hedge Fund | 1.0752 | 810145 | 292666 | 2023-03-31 | HIGH |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.0483 | 789912 | -677367 | 2023-03-31 | LOW |
Omni Partners US LLC | Investment Advisor/Hedge Fund | 1.0216 | 769766 | 700667 | 2021-09-30 | |
Virnich (Daniel) | Individual Investor | 0.7325 | 551972 | -144542 | 2023-04-17 | MED |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.7061 | 532067 | 2447 | 2023-03-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.5569 | 419621 | 644 | 2023-03-31 | LOW |
Hively (Brad) | Individual Investor | 0.4922 | 370849 | -244864 | 2023-04-17 | LOW |
Redmile Group, LLC | Investment Advisor/Hedge Fund | 0.4221 | 318082 | -1265076 | 2023-03-31 | LOW |
Prosight Capital | Hedge Fund | 0.3741 | 281902 | 6341 | 2023-03-31 | HIGH |
Barasch (Richard A) | Individual Investor | 0.3413 | 257201 | 45904 | 2023-04-17 | LOW |
Agajanian (Richy) | Individual Investor | 0.3363 | 253436 | 0 | 2023-03-31 | |
Pacala (Mark L.) | Individual Investor | 0.3227 | 243155 | 154756 | 2023-04-17 | HIGH |
Waarom Capital.com? De cijfers spreken voor zichzelf.
Capital.com Group535K+
Handelaren
87K+
Actieve klanten per maand
$113M+
Maandelijks beleggingsvolume
$64M+
Opgenomen per maand
Handelscalculator
Bereken uw virtuele winst- en verliesrekening indien u een CFD-positie had geopend op een bepaalde datum (kies een datum) en gesloten op een andere datum (kies een datum).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
The Oncology Institute, Inc. Company profile
Over The Oncology Institute, Inc.
The Oncology Institute, Inc., voorheen DFP Healthcare Acquisitions Corp., is een oncologiebedrijf. Het bedrijf beheert oncologiepraktijken in de gemeenschap die patiënten bedienen in ongeveer 55 klinieklocaties verspreid over acht markten en vier staten in de Verenigde Staten. De door het bedrijf beheerde klinieken bieden een scala aan medische oncologiediensten, waaronder diensten van artsen, een eigen infuus en apotheek, diensten op het gebied van klinische proeven, programma's zoals ambulante stamceltransplantaties en transfusies, samen met 24/7 ondersteuning van patiënten. Via het Innovative Clinical Research Institute (ICRI), levert en beheert de Vennootschap ook diensten op het gebied van klinische proeven en onderzoek ten behoeve van kankerpatiënten. Haar diensten, zoals het beheer van klinische studies, palliatieve zorgprogramma's en stamceltransplantaties, zijn toegankelijk via academische en tertiaire zorginstellingen. Haar beheerde klinieken bedienen hoofdzakelijk volwassen en oudere kankerpatiënten in markten die Medicare Advantage (MA) plannen hebben.
Industry: | Healthcare Facilities & Services (NEC) |
18000 Studebaker Rd
Suite 800
CERRITOS
CALIFORNIA 90703
US
Winst- en verliesrekening
- Annual
- Quarterly
Mensen bekijken ook
Nog steeds op zoek naar een broker die u kunt vertrouwen?
Sluit u aan bij de 535.000+ handelaren die er wereldwijd voor kozen om met Capital.com te handelen